Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$25.36
+4.5%		$25.33
$20.46
▼
$48.78
$12.55B1.6613.90 million shs1.41 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$59.86
+0.1%		$60.55
$22.28
▼
$85.60
$23.88B0.918.66 million shs1.33 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
+1.00%+3.28%-8.35%-1.38%-43.40%
Moderna, Inc. stock logo
MRNA
Moderna
+1.08%+8.47%-12.39%+12.28%+128.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$25.36
+4.5%		$25.33
$20.46
▼
$48.78
$12.55B1.6613.90 million shs1.41 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$59.86
+0.1%		$60.55
$22.28
▼
$85.60
$23.88B0.918.66 million shs1.33 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
+1.00%+3.28%-8.35%-1.38%-43.40%
Moderna, Inc. stock logo
MRNA
Moderna
+1.08%+8.47%-12.39%+12.28%+128.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DraftKings Inc. stock logo
DKNG
DraftKings
2.73
Moderate Buy$34.0534.25% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.88
Reduce$42.13-29.61% Downside

Current Analyst Ratings Breakdown

Latest MRNA and DKNG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$29.00
8/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Northland Securities logo
Northland Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$28.00
8/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$35.00 ➝ $33.00
8/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$35.00 ➝ $34.00
8/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$34.00 ➝ $33.00
8/7/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/7/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$29.00 ➝ $30.00
8/6/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$27.00
8/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DraftKings Inc. stock logo
DKNG
DraftKings
$6.05B2.08$0.78 per share32.39$1.27 per share19.97
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B12.29N/AN/A$22.14 per share2.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DraftKings Inc. stock logo
DKNG
DraftKings
$3.71M-$0.38N/A20.29N/A-2.68%-10.88%-1.59%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%N/A

Latest MRNA and DKNG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DraftKings Inc. stock logo
DKNG
DraftKings
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DraftKings Inc. stock logo
DKNG
DraftKings
3.03
1.02
1.02
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
37.70%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
47.18%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
DraftKings Inc. stock logo
DKNG
DraftKings
5,500496.13 million262.06 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
August 11 at 1:23 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-approval-mflusiva-highlights-moderna-160142079.html
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
August 10 at 8:22 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
August 10 at 3:17 PM  |  clinicaltrialsarena.comC
A new flu vaccine geared to older people is coming soon
August 10 at 9:22 AM  |  lpm.orgL
Moderna: I'm Still On Sell, But Here's What Would Change My Mind
August 10 at 7:30 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4933986-moderna-stock-still-sell-what-would-change-my-mind
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.
August 10 at 4:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moderna-inc-mrna-shares-acquired-by-contravisory-investment-management-inc-2026-08-10/
FDA Approves First mRNA Flu Vaccine for Adults 50 and Older
August 9 at 8:32 AM  |  everydayhealth.comE
Moderna’s mFlusiva Approved as First mRNA-Based Influenza Vaccine
August 8 at 7:55 AM  |  rheumatologyadvisor.comR
The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not get it.
August 8 at 7:55 AM  |  newsday.comN
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off
August 8 at 7:55 AM  |  thedailyupside.comT
Moderna, Inc. $MRNA Shares Acquired by Empowered Funds LLC
August 8 at 3:38 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moderna-inc-mrna-shares-acquired-by-empowered-funds-llc-2026-08-08/
Moderna (MRNA) Q2 2026 Earnings Call Transcript
August 7, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/07/moderna-mrna-q2-2026-earnings-call-transcript/
Moderna wins FDA approval for first mRNA-based flu shot
August 7, 2026  |  americanbazaaronline.comA
5 things to know about Moderna’s new mRNA flu vaccine
August 7, 2026  |  triblive.comT
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-greenlit-mrna-flu-vaccine-040100067.html
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-q2-earnings-call-highlights-144500762.html
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971092/moderna-q2-earnings-call-highlights-cost-cuts-and-pipeline-milestones?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2971092
FDA Approves New, More Effective Flu Vaccine From Moderna
August 7, 2026  |  aol.comA
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
August 7, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/moderna-mrna-flu-shot-wins-103350882.html
FDA approves Moderna's mRNA flu vaccine after initial pushback
August 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/fda-approves-modernas-mrna-flu-vaccine-after-initial-pushback/ar-AA29uchU
Moderna (MRNA) Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-mrna-starts-phase-1-131158123.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

DraftKings stock logo

DraftKings NASDAQ:DKNG

$25.36 +1.09 (+4.49%)
As of 10:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting and casino, daily fantasy sports, media, and other consumer products, as well as retails sportsbooks. The company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. In addition, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT drops and supports secondary-market transactions. The company is headquartered in Boston, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$59.86 +0.05 (+0.08%)
As of 10:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas